Daniel Khalaf

Medical Oncologist at BC Cancer Vancouver

[Daniel Khalaf @DKhalafMD]

Time to consider reduced enza dosing in elderly? Our study showed 1/3 require a dose reduction, largely for fatigue, but nonetheless better outcomes c/w abi

[Maryam Soleimani MD @MSoleimani_MD]

Now in EJC! Our analysis of abi v enza in men 80+ with #prostatecancer
✅Higher PSA RR, longer TTP with enza despite more dose red & higher d/c rate
✅Dose mod a useful strategy to balance toxicity & clinical benefit @DKhalafMD @OncoAlert @OncologyAdvance https://t.co/euX0nw5UBF

[Daniel Khalaf @DKhalafMD]

So thankful to @PCF_Science for this recognition, and honored to be amongst this stellar group of 2020 YIs!

[PCF Science @PCF_Science]

ANNOUNCING the 2020 Class of @PCFnews Young Investigators!

Congratulations to these stellar early career #ProstateCancer physicians and scientists who are dedicating their careers to prostate cancer research & developing new treatments for patients!

https://t.co/gAQMYnn5NJ

[Daniel Khalaf @DKhalafMD]

@ResearchWyatt @LuciaNappi4 I owe a huge debt of gratitude to you @ResearchWyatt and Dr Kim Chi for the great mentorship

[Daniel Khalaf @DKhalafMD]

@ResearchWyatt @mattsydes @scserendipity1 @AdamSharpMedOnc @PCF_Science @The_MRC @Prof_Nick_James @ChrisSweens1 @soulehoward1 @CaPsurvivorship @EUplatinum Great question, and this was a strength of the 1st line QOL study: questionnaire response rate generally above 90-95% over the 24 weeks assessed (suppl table 2)

[Daniel Khalaf @DKhalafMD]

@PCF_Science 2/2 Patient selection is key: if primary resistance to 1st line abi, significant pain, high burden of mets or visceral mets, would prefer switch to chemo

[Daniel Khalaf @DKhalafMD]

@PCF_Science 1/2 In our trial, we switched treatments in most cases at PSA progression before rad or clin progression. Early switch may be a good strategy for 2nd line hormonal agent.

[Daniel Khalaf @DKhalafMD]

@PCF_Science @ResearchWyatt @LoebStacy @AzadOncology @marty_gleave @VanProstateCtr @PCFnews @PCF_select @soulehoward1 3/3 Also noteworthy: First-line time to PSA progression similar for both agents, despite better first-line PSA response rate for enza

[Daniel Khalaf @DKhalafMD]

@PCF_Science @ResearchWyatt @LoebStacy @AzadOncology @marty_gleave @VanProstateCtr @PCFnews @PCF_select @soulehoward1 1/3 Major finding of this first-line study in mCRPC: treatment sequence of abiraterone followed by enzalutamide had better time to PSA progression vs opp sequence,

[Daniel Khalaf @DKhalafMD]

@PCF_Science @ResearchWyatt @LoebStacy @AzadOncology @marty_gleave @VanProstateCtr @PCFnews @PCF_select @soulehoward1 2/3 driven by second-line activity of enza (36% PSA decline of 30%) vs minimal activity for second-line abi (4% PSA decline), in largely docetaxel-naïve patients.